Advancing a New Era of CNS Therapeutics

Utilizing our unique di si-RNA platform, Atalanta Therapeutics is dedicated to finding solutions for intractable diseases of the central nervous system. Our pipeline is composed of programs addressing diseases with significant unmet need with the potential to improve the lives of millions of patients around the world.

Disease Area stage in the processDisease Area

Target stage in the processTarget

Discovery stage in the processDiscovery

Pre-Clinical stage in the processPre-Clinical

IND Enabling stage in the processIND Enabling

Phase 1 stage in the processPhase 1

Product Rights stage in the processProduct Rights

Epilepsy

KCNT1 (ATL-201)

Genetic Epilepsy

KCNT1 (ATL-201) is currently in IND Enabling stage

Huntington’s Disease

Pan HTT (ATL-101)

Huntington’s Disease

Pan HTT (ATL-101) is currently in Pre-Clinical stage

MSH3

Huntington’s Disease

MSH3 is currently in Discovery stage

Pain

NAV 1.7 (ATL-301)

Multiple Indications

NAV 1.7 (ATL-301) is currently in Pre-Clinical stage

Alzheimer’s Disease

APOE

Alzheimer’s Disease

APOE is currently in Discovery stage

CD33

Alzheimer’s Disease

CD33 is currently in Discovery stage

CNS Disorders

Undisclosed

Multiple Targets

Undisclosed is currently in Discovery stage
Product Rights
atalanta Logo

CNS Disorders

Undisclosed

Multiple Targets

Undisclosed is currently in Pre-Clinical stage
Product Rights
Genentech logo
Your browser is out of date!

Update your browser to view this website correctly. Update my browser now